Case Western Reserve University

The University of Texas System

University of Kentucky Research Foundation

Other

The Penn State Research Foundation

Osiris Therapeutics, Inc.

Stanton L Gerson

Lili Liu

Sanford D Markowitz

Amar Desai

Joseph Ready

Monika Antczak

Bruce Posner

Arnold I Caplan

Stephen E Haynesworth

James K V Willson

Yongyou Zhang

Sung Yeun Yang

KiBeom Bae

Yanming Wang

Hsin-Hsiung Tai

William Greenlee

Anthony E Pegg

Melissa Moss

Hillard M Lazarus

Won Jin Ho

Herbert Y Meltzer

Allison G Condie

Youngyou Zhang

James Kv Wilson

Yan Yan

James KV Willson

Bruce A Posner

Kibeom Bae

A method of treating or preventing a fibrotic disease, disorder or condition includes administering to a subject in need of treatment a 15-PGDH inhibitor.

Inhibitors of short-chain dehydrogenase activity for treating fibrosis

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

Compositions and methods of modulating short-chain dehydrogenase activity

A method of determining the susceptibility of a cancer in a subject to treatment with an antimetabolite includes obtaining a sample of cancer cells from the subject, measuring the level of UDG expression in the cancer cells, and comparing the measured levels of UDG expression in the cancer cells to a control level.

Methods of diagnosing and treating cancer

A method of treating cancer in a subject includes determining the p53 status and the level of UDG in cancer cells of the subject and administering an antimetabolite agent in combination with an AP endonuclease inhibitor or UDG inhibitor if the determined level of UDG in the cancer cells is increased relative to the control level and the cancer cells are p53 mutant or deficient cancer cells.

A fluorescent probe for binding to and detection of AP sites of DNA includes the following formula: F-L-X where F is a fluorescent moiety, X is an aminooxy group (&#x2014;ONH), and L is a linker that links or couples the fluorescent moiety to the oxyamine.

Fluorescent probes for abasic site detection

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein.

Compositions and methods of modulating 15-PGDH activity

A method of modulating hematopoietic stem cells and hematopoiesis includes administering to a subject in need thereof a 15-PGDH inhibitor.

Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis

A method treating cancer in a subject comprises administering to the subject a therapeutically effective amount of an antimetabolite agent that induces formation of AP sites in cancer cells of the subjects and an amount AP endonuclease inhibitor effective to potentiate the cytotoxicity of the antimetabolite agent to the cancer cells.

Antimetabolite agent combinations in the treatment of cancer

A method of treating a neoplastic disease in a subject includes administering to neoplastic cells of the subject an MGMT inhibitor and at least one of an antimitotic agent or a DNA damaging agent.

MGMT inhibitor combination for the treatment of neoplastic disorders

This application provides compositions and methods useful in the treatment of certain cancers. In part, this application is based on the recognition that certain molecules that target abasic lesions or AP sites in DNA improve, augment, or potentiate the chemotherapeutic efficacy of certain anticancer agents.

Alkylating agent combinations in the treatment of cancer

A method of measuring the efficacy of an anticancer agent in generating abasic (AP) sites in DNA of cancer cells of a subject includes administering to the subject an anticancer agent that generates AP sites in at least one cancer cell and an AP endonuclease inhibitor probe. The AP endonuclease inhibitor probe includes a detection moiety for detecting the probe in the subject. The amount of probe bound to cancer cells of the subject is then measured. The amount of probe bound to cancer cells of the subject is indicative of efficacy of the anticancer agent in generating AP sites in cancer cells of the subject.

Detection and quantification of abasic site formation in vivo

Genetically engineered hematopoietic progenitor cells that carry within them genes of interest, particularly for the expression of physiologically or pharmacologically active proteins. The hematopoietic progenitor cells are transduced in the presence of human mesenchymal stem cells which enhance transduction efficiency.

Growing community of inventors

Pepper Pike, OH, United States of America

Stanton L Gerson